Cryo-Cell International, Inc. (CCEL)
NYSE American
Price as at 30 Sept 2026, 16:54 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Cryo-Cell International, Inc. trades at $4.20. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Cryo-Cell International, Inc.
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its CCEL data?
Fundamentals for CCEL come from company filings and exchange data, as listed on NYSE American; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:54 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CCEL, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.